TRVNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:36):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
本日の出来高	8 290.00
平均出来高	211 079
時価総額	5.99M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-0.470 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0700
ATR14	$0.00600 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.78
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

ボリューム相関

長: -0.13 (neutral)

短: -0.40 (neutral)

Signal:(51.689) Neutral

Trevena Inc 相関

10 最も正の相関
AVO	0.962
SWVL	0.94
RPID	0.938
QLGN	0.938
ARQQ	0.936
XFOR	0.934
LYRA	0.932
ASPS	0.932
ALZN	0.93
GOSS	0.929

10 最も負の相関
STAY	-0.95
ACAB	-0.943
GLLI	-0.942
FNVT	-0.939
HZNP	-0.937
CIIG	-0.936
AVAC	-0.933
NWFL	-0.931
TIPT	-0.929
LRFC	-0.929

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Trevena Inc 相関 - 通貨/商品

-0.65
( weak negative )

-0.80
( strong negative )

0.00
( neutral )

0.56
( weak )

Trevena Inc 財務諸表

Annual	2022
収益:	$-418 000
総利益:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2022
収益:	$-418 000
総利益:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
収益:	$567.00
総利益:	$-387.00 (-68.25 %)
EPS:	$-0.0101

FY	2020
収益:	$3.07M
総利益:	$2.89M (94.07 %)
EPS:	$-5.75

Financial Reports:

No articles found.

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.